MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MBX Biosciences (NASDAQ:MBX) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other research analysts have also recently commented on MBX. UBS Group reiterated a “buy” rating on shares of MBX Biosciences in a report on Tuesday, February 24th. TD Cowen reiterated a “buy” rating on shares of MBX Biosciences in a report on Thursday, March 12th. Barclays started coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Finally, Guggenheim increased their price target on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $55.75.

MBX Biosciences Trading Down 2.2%

NASDAQ:MBX opened at $40.08 on Friday. MBX Biosciences has a twelve month low of $9.43 and a twelve month high of $45.85. The company has a 50-day moving average of $31.18 and a 200-day moving average of $31.40. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -18.14 and a beta of 0.78.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.15. On average, research analysts forecast that MBX Biosciences will post -2.9 earnings per share for the current year.

Insiders Place Their Bets

In other MBX Biosciences news, CEO P. Kent Hawryluk acquired 18,500 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average price of $28.41 per share, with a total value of $525,585.00. Following the completion of the transaction, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. The trade was a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Institutional Investors Weigh In On MBX Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new stake in MBX Biosciences during the first quarter worth $1,396,000. Swiss National Bank acquired a new position in MBX Biosciences in the first quarter valued at about $1,325,000. Bank of New York Mellon Corp boosted its position in MBX Biosciences by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 80,222 shares of the company’s stock valued at $2,395,000 after buying an additional 4,960 shares in the last quarter. Candriam S.C.A. acquired a new position in MBX Biosciences in the first quarter valued at about $8,787,000. Finally, Strs Ohio boosted its position in MBX Biosciences by 128.6% in the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after buying an additional 900 shares in the last quarter.

MBX Biosciences News Summary

Here are the key news stories impacting MBX Biosciences this week:

• Positive Sentiment: MBX Biosciences released an obesity portfolio update showing initial Phase 1 data for MBX 4291, including preliminary blinded results that supported the potential for once-monthly dosing. The early data also showed mean weight loss of 7% at 8 weeks in the first cohort, which may strengthen confidence in the company’s lead obesity asset. Article Title
• Positive Sentiment: Truist Financial raised its price target on MBX to $70 from $50 and reiterated a buy rating, signaling improved analyst confidence in the stock’s upside potential. Article Title
• Neutral Sentiment: A Seeking Alpha transcript highlighted MBX’s discussion of novel approaches and clinical progress in its obesity therapeutics portfolio, reinforcing investor focus on the company’s pipeline but without a clear new catalyst. Article Title
• Neutral Sentiment: Reports of short interest activity showed no meaningful short interest figures, so this does not appear to be a major driver of the stock move. Article Title
• Negative Sentiment: Broader industry commentary on Novo Nordisk and GLP-1 rivalry suggests the obesity market remains highly competitive, which could limit enthusiasm around MBX’s long-term commercialization prospects. Article Title

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.